KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Interest & Investment Income for 10 consecutive years, with $3.3 million as the latest value for Q3 2020.

  • On a quarterly basis, Interest & Investment Income fell 41.4% to $3.3 million in Q3 2020 year-over-year; TTM through Sep 2020 was $19.0 million, a 6.19% decrease, with the full-year FY2018 number at $13.8 million, up 383.34% from a year prior.
  • Interest & Investment Income was $3.3 million for Q3 2020 at Supernus Pharmaceuticals, down from $5.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $5.6 million in Q3 2019 to a low of $327000.0 in Q1 2016.
  • A 5-year average of $2.3 million and a median of $1.0 million in 2017 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 458.54% in 2018, then plummeted 41.4% in 2020.
  • Supernus Pharmaceuticals' Interest & Investment Income stood at $396000.0 in 2016, then surged by 117.68% to $862000.0 in 2017, then skyrocketed by 423.43% to $4.5 million in 2018, then rose by 23.38% to $5.6 million in 2019, then tumbled by 41.4% to $3.3 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Interest & Investment Income are $3.3 million (Q3 2020), $5.6 million (Q3 2019), and $5.4 million (Q2 2019).